biotech · WHIM Syndrome · Neutropenias · XFOR
X4 Pharmaceuticals
X4 Pharmaceuticals, Inc
X4 Pharmaceuticals is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker XFOR. Primary therapeutic focus areas include WHIM Syndrome, Neutropenias, Hepatic Insufficiency, Neutropenia, Wal
61 N Beacon St, Boston, Massachusetts 02134, US HQ
2014 Founded
81 Employees
Public company Type
XFOR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 61 N Beacon St, Boston, Massachusetts 02134, US
- Founded
- 2014
- Employees
- 81
- Programs
- 11
- Drugs
- 6
- Patents
- 16
Mavorixafor
Phase 3 · small molecule · WHIM Syndrome
Mavorixafor for WHIM Syndrome is a Phase 3 program (small_molecule) at X4 Pharmaceuticals, Inc with 1 ClinicalTrials.gov record(s).
Internal code X4P-001-103
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- X4 Pharmaceuticals, Inc
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- WHIM Syndrome
- Status
- active
- Trials
- 1